Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics extends South San Francisco HQ lease to March 2034

Neutral Impact 2 of 5 product/contract Written later

Aligos Therapeutics amended the lease for its South San Francisco headquarters, extending the term from March 31, 2027 to March 31, 2034. The amendment sets rising monthly base rent per square foot, grants a ten-month rent abatement, and gives the company an option to terminate in 2031 for a $2,476,429.22 fee.

Key points

  • Lease term extended from March 31, 2027 to March 31, 2034, with base rent of $4.650 to $5.716 per rentable square foot per month
  • Ten-month rent abatement from April 1, 2027 to January 31, 2028, if there is no material default
  • One-time option to terminate as of March 31, 2031, with notice by March 31, 2030 and $2,476,429.22 termination consideration

The filing

CompanyAligos Therapeutics, Inc. (ALGS)
Form8-K, current report
Filed with the SECSep 15, 2026, 4:03 PM ET
Accession number0001193125-26-391880

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.